



BIODIEM LTD
ABN 20 096 845 993
Suite 3, Level 11,
470 Collins Street,
Melbourne, Victoria, 3000
Australia
Phone: +613 9613 4100
Web: www.biodiem.com

ASX Announcement

BioDiem to present at Hong Kong biotech investment forum

Melbourne, 4 June 2013: Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) is presenting to Asian investors as part of biotech and partnering forum *Asia Biotech Invest 2013*, held at the Sheraton Hotel and Towers in Hong Kong from June 3 – 5, 2013.

BioDiem CEO Julie Phillips will present on BioDiem's commercial programs and technology pipeline, business model and investment and partnership opportunities at 10.15am (HKT) on Tuesday 4 June.

"Asia Biotech Invest is a key event for investment and capital raising, bringing together potential investors and biotech leaders. It provides an opportunity to build awareness of our commercial flu programs and technology portfolio in a strong Asian market," CEO Julie Phillips said.

"Our influenza vaccine technology is already generating revenues through partnerships in India and China. The next commercial opportunity is our patented antimicrobial, BDM-I, which is currently in preclinical proof-of-concept studies for a range of hard-to-treat infectious diseases. We have made significant progress in the last six months and I look forward to sharing these insights with potential partners and investors."

The information presented at Asia Biotech Invest will be available on the ASX post-event. For additional information, please visit www.biodiem.com

ENDS

About BioDiem Ltd

BioDiem (ASX: BDM) is an ASX-listed biopharmaceutical company which is developing vaccines and antimicrobials for the treatment or prevention of infectious diseases, and related cancers. Their lead technology is the LAIV (Live Attenuated Influenza Virus) used for seasonal and pandemic influenza vaccines, and which is administered intranasally. A project develop a therapeutic hepatitis vaccine, targeting hepatitis D and B, is underway at the University of Canberra. BioDiem has an antimicrobial, BDM-I, which is in preclinical development for fungal and bacterial diseases as well as schistosomiasis, tuberculosis and protozoal infections. The company also has SAVINE (scrambled antigen) technology which is in development to address tuberculosis and also Epstein-Barr virus (EBV) related disease including nasopharyngeal cancer. BioDiem also has a retinal product, BDM-E, which is in development for retinitis pigmentosa and is available for outlicence.

BioDiem's research is ongoing in partnerships with internationally recognised laboratories and commercial groups.

For additional information, please visit www.biodiem.com

Contact

Investors

Julie Phillips, Chief Executive Officer
BioDiem Ltd
Phone +61 3 9613 4100
Email jphillips@biodiem.com

Media

Shevaun Cooper
Buchan Consulting
Phone +61 3 8866 1218 / +61 (0) 421 760 775
Email scooper@buchanwe.com.au